TESARO, Inc. (NASDAQ:TSRO) was the recipient of a significant decrease in short interest in the month of September. As of September 29th, there was short interest totalling 6,767,191 shares, a decrease of 28.5% from the September 15th total of 9,459,637 shares. Approximately 17.9% of the shares of the stock are short sold. Based on an average trading volume of 570,698 shares, the short-interest ratio is presently 11.9 days.

In other news, VP Grant C. Bogle sold 14,167 shares of the company’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Edward C. English sold 10,862 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total value of $1,465,501.04. Following the completion of the transaction, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,692 shares of company stock valued at $4,628,976. Corporate insiders own 40.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Achmea Investment Management B.V. purchased a new stake in shares of TESARO during the 2nd quarter valued at approximately $234,000. Public Employees Retirement System of Ohio raised its position in shares of TESARO by 82.4% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 36,667 shares of the biopharmaceutical company’s stock valued at $5,128,000 after buying an additional 16,569 shares during the period. Intellectus Partners LLC raised its position in shares of TESARO by 17.7% during the 2nd quarter. Intellectus Partners LLC now owns 6,310 shares of the biopharmaceutical company’s stock valued at $883,000 after buying an additional 950 shares during the period. California State Teachers Retirement System raised its position in shares of TESARO by 20.8% during the 2nd quarter. California State Teachers Retirement System now owns 68,090 shares of the biopharmaceutical company’s stock valued at $9,523,000 after buying an additional 11,706 shares during the period. Finally, Cubist Systematic Strategies LLC raised its position in shares of TESARO by 291.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 7,105 shares of the biopharmaceutical company’s stock valued at $994,000 after buying an additional 5,291 shares during the period.

Shares of TESARO (TSRO) opened at 121.23 on Friday. The stock’s market capitalization is $6.57 billion. The firm’s 50-day moving average price is $122.29 and its 200-day moving average price is $134.29. TESARO has a 12 month low of $106.64 and a 12 month high of $192.94.

TESARO (NASDAQ:TSRO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). The company had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The company’s revenue for the quarter was down 17.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.28) earnings per share. On average, equities research analysts forecast that TESARO will post ($8.63) EPS for the current year.

TSRO has been the subject of a number of recent analyst reports. Cowen and Company dropped their price objective on TESARO from $145.00 to $124.00 and set a “market perform” rating for the company in a research note on Monday, June 19th. Bank of America Corporation reissued a “buy” rating and set a $154.00 price target on shares of TESARO in a research note on Tuesday, June 20th. Wells Fargo & Company reissued an “outperform” rating and set a $236.00 price target on shares of TESARO in a research note on Tuesday, June 20th. Leerink Swann dropped their price target on TESARO from $164.00 to $143.00 and set a “market perform” rating for the company in a research note on Tuesday, June 20th. Finally, Raymond James Financial, Inc. reissued a “market perform” rating on shares of TESARO in a research note on Tuesday, June 20th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $170.19.

TRADEMARK VIOLATION NOTICE: “TESARO, Inc. (TSRO) Short Interest Update” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/13/tesaro-inc-tsro-short-interest-update.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.